- Home
- NMRA
as 02-21-2025 4:00pm EST
Stocks
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 287.6M | IPO Year: | 2023 |
| Target Price: | $20.67 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.86 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.60 - $21.00 | Next Earning Date: | 03-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Neumora Therapeutics Inc. (NMRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lenz Robert A. | NMRA | Head of R&D | Feb 18 '25 | Sell | $1.67 | 5,614 | $9,383.24 | 309,092 | |
| Aurora Daljit Singh | NMRA | Chief Strategy Officer | Feb 18 '25 | Sell | $1.68 | 8,565 | $14,347.23 | 88,935 | |
| Milligan Michael Lee | NMRA | See Remarks | Feb 18 '25 | Sell | $1.69 | 1,978 | $3,350.53 | 22,470 | |
| Pinto Joshua | NMRA | President | Feb 18 '25 | Sell | $1.67 | 8,048 | $13,477.18 | 76,952 | |
| BERNS PAUL L | NMRA | See Remarks | Feb 18 '25 | Sell | $1.69 | 13,871 | $23,468.34 | 7,405,004 |
Latest Neumora Therapeutics Inc. News
NMRA Breaking Stock News: Dive into NMRA Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
3 US Penny Stocks With Market Caps Below $400M
BioPharma Dive
9 days ago
Neumora shakes up its C-suite; Biogen cuts early-stage pipeline
MT Newswires
9 days ago
Neumora Therapeutics Names Paul Berns as CEO, Michael Milligan as CFO
GlobeNewswire
9 days ago
Neumora Therapeutics Announces Leadership Transition
Simply Wall St.
a month ago
3 US Penny Stocks With Market Caps Over $30M To Watch
Zacks
a month ago
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
TipRanks
2 months ago
Neumora shares look oversold after 80% drop, says Mizuho
MT Newswires
2 months ago
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Compare NMRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NMRA Neumora Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.